Franz H. Messerli

Franz H. Messerli

Auto-generated profile, based on publicly available information

Franz H. Messerli

Department of Cardiology, Kantonsspital Luzern, Luzern, Switzerland

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in JACC: Heart Failure
Verified
Journal Article
Closed access
FMFranz H. Messerli
Franz H. Messerli
SRStefano F. Rimoldi
Stefano F. Rimoldi
SBSripal Bangalore
Sripal Bangalore

23 December 2013 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SRStefano F. Rimoldi
Stefano F. Rimoldi
USUrs Scherrer
Urs Scherrer
FMFranz H. Messerli
Franz H. Messerli
Secondary hypertension refers to arterial hypertension due to an identifiable cause and affects ∼5–10% of the general hypertensive population. Because secondary forms are rare and work up is time-consuming and expensive, only patients with clinical suspicion should be screened. In recent years, some new aspects gained importance regarding this screening. In particular, increasing evidence suggests that 24 h ambulatory blood pressure (BP) monitoring plays a central role in the work up of patients with suspected secondary hypertension. Moreover, obstructive sleep apnoea has been identified as one of the most frequent causes. Finally, the introduction of catheter-based renal denervation for the treatment of patients with resistant hypertension has dramatically increased the interest and the number of patients evaluated for renal artery stenosis. We review the clinical clues of the most common causes of secondary hypertension. Specific recommendations are given as to evaluation and treatment of various forms of secondary hypertension. Despite appropriate therapy or even removal of the secondary cause, BP rarely ever returns to normal with long-term follow-up. Such residue hypertension indicates either that some patients with secondary hypertension also have concomitant essential hypertension or that irreversible vascular remodelling has taken place. Thus, in patients with potentially reversible causes of hypertension, early detection and treatment are important to minimize/prevent irreversible changes in the vasculature and target organs.

1 April 2018 in JACC
Verified
Journal Article
Closed access
FMFranz H. Messerli
Franz H. Messerli
SBSripal Bangalore
Sripal Bangalore
CBChirag Bavishi
Chirag Bavishi
SRStefano F. Rimoldi
Stefano F. Rimoldi

25 September 2012 in The Journal of Clinical Hypertension
Verified
Journal Article
Closed access
PDF file
Alexandros BriasoulisAlexandros Briasoulis
Alexandros Briasoulis
VAVikram Agarwal
Vikram Agarwal
FMFranz H. Messerli
Franz H. Messerli

28 January 2013 in BMJ
Verified
Journal Article
Open access
PDF file
HMHarikrishna Makani
Harikrishna Makani
SBSripal Bangalore
Sripal Bangalore
KDK. A. Desouza
K. A. Desouza
ASArpit Shah
Arpit Shah
FMFranz H Messerli
Franz H Messerli
Objective To compare the long term efficacy and adverse events of dual blockade of the renin-angiotensin system with monotherapy. Design Systematic review and meta-analysis. Data sources PubMed, Embase, and the Cochrane central register of controlled trials, January 1990 to August 2012. Study selection Randomised controlled trials comparing dual blockers of the renin-angiotensin system with monotherapy, reporting data on either long term efficacy (≥1 year) or safety events (≥4 weeks), and with a sample size of at least 50. Analysis was stratified by trials with patients with heart failure versus patients without heart failure. Results 33 randomised controlled trials with 68 405 patients (mean age 61 years, 71% men) and mean duration of 52 weeks were included. Dual blockade of the renin-angiotensin system was not associated with any significant benefit for all cause mortality (relative risk 0.97, 95% confidence interval 0.89 to 1.06) and cardiovascular mortality (0.96, 0.88 to 1.05) compared with monotherapy. Compared with monotherapy, dual therapy was associated with an 18% reduction in admissions to hospital for heart failure (0.82, 0.74 to 0.92). However, compared with monotherapy, dual therapy was associated with a 55% increase in the risk of hyperkalaemia (P<0.001), a 66% increase in the risk of hypotension (P<0.001), a 41% increase in the risk of renal failure (P=0.01), and a 27% increase in the risk of withdrawal owing to adverse events (P<0.001). Efficacy and safety results were consistent in cohorts with and without heart failure when dual therapy was compared with monotherapy except for all cause mortality, which was higher in the cohort without heart failure (P=0.04 v P=0.15), and renal failure was significantly higher in the cohort with heart failure (P<0.001 v P=0.79). Conclusion Although dual blockade of the renin-angiotensin system may have seemingly beneficial effects on certain surrogate endpoints, it failed to reduce mortality and was associated with an excessive risk of adverse events such as hyperkalaemia, hypotension, and renal failure compared with monotherapy. The risk to benefit ratio argues against the use of dual therapy.

15 March 2011 in European Heart Journal
Verified
Journal Article
Open access
PDF file
FMFranz H. Messerli
Franz H. Messerli
SBSripal Bangalore
Sripal Bangalore
HMHarikrishna Makani
Harikrishna Makani
SRStefano F. Rimoldi
Stefano F. Rimoldi
YAYves Allemann
Yves Allemann
PSPeter Sleight
Peter Sleight
In 1988 Pickering et al. reported in the Lancet a series of 11 hypertensive patients with bilateral atheromatous renovascular disease who presented with a history of multiple episodes of pulmonary oedema.1 Seven of these patients had stenosis of both renal arteries and in a subsequent series of 90 patients, pulmonary oedema was significantly more common in patients with bilateral than in those with unilateral renal artery stenosis (RAS).2 Successful revascularization of one or both renal arteries eliminated pulmonary oedema in 77% of patients with bilateral RAS.2 The authors concluded that ‘bilateral RAS may be a specific and treatable predisposing factor to pulmonary oedema in azotemic hypertensive patients'.1 Since the initial observation of this clinical entity 29 case reports,3–31 9 case series,1,32–39 and 10 clinical studies1–2,40–47 of flash pulmonary oedema (FPO) and RAS (both unilateral and bilateral) have been published of which 16 case reports, 2 case series, and 7 clinical studies comprising a total of 87 patients relate to bilateral RAS and FPO. The underlying pathophysiological mechanisms responsible for triggering FPO in patients with bilateral RAS have been delineated in several clinical and experimental studies. Since FPO and bilateral RAS seem to be a unique entity with distinct pathophysiological, clinical, and therapeutic features, we propose to name it Pickering Syndrome. In the following, we review incidence, pathophysiology, clinical findings, and treatment of the Pickering Syndrome.